Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 22, 2025 06:00 ET | Source: R3 Vascular

R3 Vascular Announces First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using MAGNITUDE® Drug Eluting Bioresorbable Scaffold

MOUNTAIN VIEW, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating...
January 13, 2025 06:00 ET | Source: R3 Vascular

R3 Vascular Secures WCG IRB Approval and CMS Category B Medicare Coverage for the ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease

MOUNTAIN VIEW, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating...
November 04, 2024 06:00 ET | Source: R3 Vascular

FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease

MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating...
July 09, 2024 14:25 ET | Source: R3 Vascular

R3 Vascular Appoints Josh Smale as its Vice President of Global Clinical and Scientific Affairs

R3 Vascular Inc. is pleased to announce the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs.
May 09, 2024 12:00 ET | Source: R3 Vascular

R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new President and CEO

R3 Vascular, Inc. announced the closing of its $87 million Series B financing round and the appointment of a new President and Chief Executive Officer
September 24, 2018 07:59 ET | Source: Amaranth Medical, Inc.

Amaranth Presented MAGNITUDE (98 micron) Nine-Month Follow-up Clinical Results and Introduced DEFIANCE (85 micron) BRS Development Plan at TCT

MOUNTAIN VIEW, CA , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Amaranth Medical, a medical device company developing next-generation bioresorbable scaffolds, provided an update on the company’s...